Antidepressant-like Activity of the Fatty Acid Amide Hydrolase Inhibitor URB597 in a Rat Model of Chronic Mild Stress

Biological Psychiatry

Volumn 62, Issue 10, 2007, Pages 1103-1110

  Bortolato, Marco ^a   Mangieri, Regina A ^a   Fu, Jin ^a   Kim, Janet H ^a   Arguello, Oliver ^a   Duranti, Andrea ^b   Tontini, Andrea ^b   Mor, Marco ^c   Tarzia, Giorgio ^b   Piomelli, Daniele ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF URBINO   (Italy)

^c UNIVERSITY OF PARMA   (Italy)

Author keywords

Anandamide; chronic mild stress; depression; FAAH; URB597

Indexed keywords

ANANDAMIDE; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE INHIBITOR; IMIPRAMINE; SUCROSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFECT; MAJOR DEPRESSION; MALE; MESENCEPHALON; NONHUMAN; PRIORITY JOURNAL; RAT; SUGAR INTAKE; THALAMUS; THERAPY EFFECT; TRANQUILIZING ACTIVITY; TREATMENT OUTCOME; TREATMENT RESPONSE; WEIGHT GAIN;

AMIDOHYDROLASES; ANIMALS; ANTIDEPRESSIVE AGENTS; BEHAVIOR, ANIMAL; BENZAMIDES; BODY WEIGHT; BRAIN; CARBAMATES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOCANNABINOIDS; GENE EXPRESSION REGULATION; IMIPRAMINE; LIPID METABOLISM; MALE; MULTIVARIATE ANALYSIS; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; STRESS, PSYCHOLOGICAL; SUCROSE; TIME FACTORS;

EID: 34250786050     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.12.001     Document Type: Article

References (59)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders: DSM-IV (1994), American Psychiatric Press, Washington, DC
2. Arnone M., Maruani J., Chaperon F., Thiebot M.H., Poncelet M., Soubrie P., et al. Selective inhibition of sucrose and ethanol intake by SR 141716, an antagonist of central cannabinoid (CB1) receptors. Psychopharmacologyd 132 (1997) 104-106 (Berl)
3. Bekris S., Antoniou K., Daskas S., and Papadopoulou-Daifoti Z. Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. Behav Brain Res 161 (2005) 45-59
4. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., and Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science 277 (1997) 1094-1097
5. Breivogel C.S., Griffin G., Di Marzo V., and Martin B.R. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol 60 (2001) 155-163
6. Colombo G., Agabio R., Diaz G., Lobina C., Reali R., and Gessa G.L. Appetite suppression and weight loss after the cannabinoid antagonist SR 141716. Life Sci 63 (1998) 113-117
7. Cota D., Marsicano G., Tschop M., Grubler Y., Flachskamm C., Schubert M., et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 112 (2003) 423-431
8. De Pablo J.M., Parra A., Segovia S., and Guillamon A. Learned immobility explains the behavior of rats in the forced swimming test. Physiol Behav 46 (1989) 229-237
9. Devane W.A., Hanus L., Breuer A., Pertwee R.G., Stevenson L.A., Griffin G., et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science 258 (1992) 1946-1949
10. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.C., et al. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372 (1994) 686-691
11. Duncan G.E., Paul I.A., Harden T.K., Mueller R.A., Stumpf W.E., and Breese G.R. Rapid down regulation of beta adrenergic receptors by combining antidepressant drugs with forced swim: A model of antidepressant-induced neural adaptation. J Pharmacol Exp Ther 234 (1985) 402-408
12. Dziedzicka-Wasylewska M., Willner P., and Papp M. Changes in dopamine receptor mRNA expression following chronic mild stress and chronic antidepressant treatment. Behav Pharmacol 8 (1997) 607-618
13. Fegley D., Gaetani S., Duranti A., Tontini A., Mor M., Tarzia G., et al. Characterization of the fatty acid amide hydrolase inhibitor cyclohexyl carbamic acid 3'-carbamoyl-biphenyl- 3-yl ester (URB597): Effects on anandamide and oleoylethanolamide deactivation. J Pharmacol Exp Ther 313 (2005) 352-358
14. Fegley D., Kathuria S., Mercier R., Li C., Makriyannis A., Piomelli D., et al. Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A 101 (2004) 8756-8761
15. Forbes N.F., Stewart C.A., Matthews K., and Reid I.C. Chronic mild stress and sucrose consumption: Validity as a model of depression. Physiol Behav 60 (1996) 1481-1484
16. Froger N., Palazzo E., Boni C., Hanoun N., Saurini F., Joubert C., et al. Neurochemical and behavioral alterations in glucocorticoid receptor-impaired transgenic mice after chronic mild stress. J Neurosci 24 (2004) 2787-2796
17. Gelfand E.V., and Cannon C.P. Rimonabant: A selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin Investig Drugs 15 (2006) 307-315
18. Gobbi G., Bambico F.R., Mangieri R., Bortolato M., Campolongo P., Solinas M., et al. Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A 102 (2005) 18620-18625
19. Griebel G., Stemmelin J., and Scatton B. Effects of the cannabinoid CB1 receptor antagonist rimonabant in models of emotional reactivity in rodents. Biol Psychiatry 57 (2005) 261-267
20. Haidkind R., Eller M., Harro M., Kask A., Rinken A., Oreland L., et al. Effects of partial locus coeruleus denervation and chronic mild stress on behaviour and monoamine neurochemistry in the rat. Eur Neuropsychopharmacol 13 (2003) 19-28
21. Hajos N., Ledent C., and Freund T.F. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience 106 (2001) 1-4
22. Halford W.P. The essential prerequisites for quantitative RT-PCR. Nat Biotechnol 17 (1999) 835
23. Haller J., Bakos N., Szirmay M., Ledent C., and Freund T.F. The effects of genetic and pharmacological blockade of the CB1 cannabinoid receptor on anxiety. Eur J Neurosci 16 (2002) 1395-1398
24. Henn F.A., and Vollmayr B. Stress models of depression: Forming genetically vulnerable strains. Neurosci Biobehav Rev 29 (2005) 799-804
25. Hill M.N., and Gorzalka B.B. Pharmacological enhancement of cannabinoid CB1 receptor activity elicits an antidepressant-like response in the rat forced swim test. Eur Neuropsychopharmacol 15 (2005) 593-599
26. Hill M.N., Patel S., Carrier E.J., Rademacher D.J., Ormerod B.K., Hillard C.J., et al. Downregulation of endocannabinoid signaling in the hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30 (2005) 508-515
27. Hillard C.J., and Campbell W.B. Biochemistry and pharmacology of arachidonoylamide, a putative endogenous cannabinoid. J Lipid Res 38 (1997) 2383-2398
28. Hillard C.J., and Jarrahian A. The movement of N-arachidonoylethanolamine (anandamide) across cellular membranes. Chem Phys Lipids 108 (2000) 123-134
29. Holt S., Comelli F., Costa B., and Fowler C.J. Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors. Br J Pharmacol 146 (2005) 467-476
30. Jayamanne A., Greenwood R., Mitchell V.A., Aslan S., Piomelli D., and Vaughan C.W. Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models. Br J Pharmacol 147 (2006) 281-288
31. Jiang W., Zhang Y., Xiao L., Van Cleemput J., Ji S.P., Bai G., et al. Cannabinoids promote embryonic and adult hippocampus neurogenesis and produce anxiolytic- and antidepressant-like effects. J Clin Invest 115 (2005) 3104-3116
32. Kathuria S., Gaetani S., Fegley D., Valino F., Duranti A., Tontini A., et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 9 (2003) 76-81
33. Lichtman A.H., and Martin B.R. Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168 (2005) 691-717
34. Liu Y., Ishida Y., Shinoda K., and Nakamura S. Effects of repeated stress on regeneration of serotonergic and noradrenergic axons in the cerebral cortex of adult rats. Neurosci Lett 339 (2003) 227-230
35. Martin M., Ledent C., Parmentier M., Maldonado R., and Valverde O. Involvement of CB1 cannabinoid receptors in emotional behaviour. Psychopharmacology 159 (2002) 379-387 (Berl)
36. Matthews K., Forbes N., and Reid I.C. Sucrose consumption as an hedonic measure following chronic unpredictable mild stress. Physiol Behav 57 (1995) 241-248
37. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu Rev Biochem 74 (2005) 411-432
38. Mechoulam R., Ben-Shabat S., Hanus L., Ligumsky M., Kaminski N.E., Schatz A.R., et al. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol 50 (1995) 83-90
39. Mor M., Rivara S., Lodola A., et al. Cyclohexylcarbamic acid 3'- or 4'- substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: Synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem 47 (2004) 4998-5008
40. Moreau J.L. Reliable monitoring of hedonic deficits in the chronic mild stress model of depression. Psychopharmacology 134 (1997) 357-358 (Berl); discussion 371-377
41. Onaivi E.S., Ishiguro H., Sejal P., Meozzi P.A., Myers L., Tagliaferro P., et al. Methods to study the behavioral effects and expression of CB2 cannabinoid receptor and its gene transcripts in the chronic mild stress model of depression. Methods Mol Med 123 (2006) 291-298
42. Papp M., Klimek V., and Willner P. Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology 115 (1994) 441-446 (Berl)
43. Papp M., Moryl E., and Willner P. Pharmacological validation of the chronic mild stress model of depression. Eur J Pharmacol 296 (1996) 129-136
44. Patel S., and Hillard C.J. Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: Further evidence for an anxiolytic role for endogenous cannabinoid signaling. J Pharmacol Exp Ther 318 (2006) 304-311
45. Patel S., Roelke C.T., Rademacher D.J., Cullinan W.E., and Hillard C.J. Endocannabinoid signaling negatively modulates stress-induced activation of the hypothalamic-pituitary-adrenal axis. Endocrinology 145 (2004) 5431-5438
46. Paxinos G., and Watson C.R.R. The Rat Brain in Stereotaxic Coordinates (1986), Academic Press, Sydney, Australia
47. Piomelli D. The endocannabinoid system: A drug discovery perspective. Curr Opin Investig Drugs 6 (2005) 672-679
48. Pi-Sunyer F.X., Aronne L.J., Heshmati H.M., Devin J., and Rosenstock J. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: A randomized controlled trial. JAMA 295 (2006) 761-775
49. Rodgers R.J., Evans P.M., and Murphy A. Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naive and plus-maze-experienced mice. Behav Pharmacol 16 (2005) 405-413
50. Sanchis-Segura C., Cline B.H., Marsicano G., Lutz B., and Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology 176 (2004) 223-232 (Berl)
51. Stella N., Schweitzer P., and Piomelli D. A second endogenous cannabinoid that modulates long-term potentiation. Nature 388 (1997) 773-778
52. Steru L., Chermat R., Thierry B., and Simon P. The tail suspension test: A new method for screening antidepressants in mice. Psychopharmacology 85 (1985) 367-370 (Berl)
53. Sugiura T., Kondo S., Sukagawa A., Nakane S., Shinoda A., Itoh K., et al. 2-Arachidonoylglycerol: A possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun 215 (1995) 89-97
54. Tarzia G., Duranti A., Tontini A., Piersanti G., Mor M., Rivara S., et al. Design, synthesis, and structure activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors. J Med Chem 46 (2003) 2352-2360
55. Van Gaal L.F., Rissanen A.M., Scheen A.J., Ziegler O., Rossner S., and RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365 (2005) 1389-1397
56. Willner P. Validity, reliability and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology 134 (1997) 319-329 (Berl)
57. Willner P. Chronic mild stress (CMS) revisited: Consistency and behavioural-neurobiological concordance in the effects of CMS. Neuropsychobiology 52 (2005) 90-110
58. Willner P., Moreau J.L., Nielsen C.K., Papp M., and Sluzewska A. Decreased hedonic responsiveness following chronic mild stress is not secondary to loss of body weight. Physiol Behav 60 (1996) 129-134
59. Willner P., Towell A., Sampson D., Sophokleous S., and Muscat R. Reduction of sucrose preference by chronic unpredictable mild stress, and its restoration by a tricyclic antidepressant. Psychopharmacology 93 (1987) 358-364 (Berl)